Prosecution Insights
Last updated: April 19, 2026

VICORE PHARMA AB

5 pending office actions

Portfolio Summary

5
Total Pending OAs
1
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18577856 NEW SELECTIVE ANGIOTENSIN II COMPOUNDS MCDOWELL, BRIAN E 1624 Non-Final OA Jan 09, 2024
18023164 NOVEL COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II COLEMAN, BRENDA LIBBY 1624 Non-Final OA Oct 10, 2023
18283489 SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS SANCHEZ, JUSTIN CHRISTOPHER 1622 Non-Final OA Sep 22, 2023
17924877 PROCESS FOR THE SYNTHESIS OF N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1- YLMETHYLPHENYL)-5-ISO-BUTYLTHIOPHENE-2-SULFONAMIDE ANDERSON, REBECCA L 1626 Non-Final OA Nov 11, 2022
17920558 NEW CAPSULE COMPOSITION FOR PERORAL ADMINISTRATION TCHERKASSKAYA, OLGA V 1615 Final Rejection Oct 21, 2022

Managing VICORE PHARMA AB's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month